DOCSLIB.ORG

Antimicrobial Resistance in Companion Animal Pathogens in Australia and Assessment of Pradofloxacin on the Gut Microbiota

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antimicrobial Resistance in Companion Animal Pathogens in Australia and Assessment of Pradofloxacin on the Gut Microbiota Antimicrobial resistance in companion animal pathogens in Australia and assessment of pradofloxacin on the gut microbiota Sugiyono Saputra A thesis submitted in fulfilment of the requirements of the degree of Doctor of Philosophy School of Animal and Veterinary Sciences The University of Adelaide February 2018 Table of Contents Thesis Declaration ...................................................................................................................... iii Dedication ................................................................................................................................. iv Acknowledgement ...................................................................................................................... v Preamble .................................................................................................................................... vi List of Publications ..................................................................................................................... vii Abstract .......................................................................................................................................ix Chapter 1 General Introduction ................................................................................................. 1 1.1. Antimicrobials and their consequences ............................................................................ 2 1.2. The emergence and monitoring AMR................................................................................ 2 1.3. Effect of pradofloxacin on dysbiosis of normal microbiota in rabbits as an animal model .................................................................................................................................................. 5 1.4. Aims and objectives of the present study ......................................................................... 8 1.5. References ....................................................................................................................... 10 Chapter 2 Antimicrobial resistance in coagulase-positive staphylococci isolated from companion animals in Australia: A one year study................................................................... 14 Statement of authorship ........................................................................................................ 15 Original article ........................................................................................................................ 17 Supplementary information .................................................................................................. 35 Chapter 3 Antimicrobial resistance in clinical Escherichia coli isolated from companion animals in Australia ................................................................................................................... 38 Statement of authorship ........................................................................................................ 39 Original article ........................................................................................................................ 41 Chapter 4 Antimicrobial resistance in companion animal pathogens in Australia: a current perspective................................................................................................................................ 50 Statement of authorship ........................................................................................................ 51 Original article ........................................................................................................................ 53 Chapter 5 Metagenomic studies of gut microbial diversity and structure changes after antibiotic treatment .................................................................................................................. 75 Statement of authorship ........................................................................................................ 76 Original article ........................................................................................................................ 78 Chapter 6 Faecal microbiota profiling in rabbits following single and multiple doses of oral pradofloxacin .......................................................................................................................... 105 Statement of authorship ...................................................................................................... 106 Original article ...................................................................................................................... 108 Supplementary information ................................................................................................ 125 Chapter 7 Oral pradofloxacin has limited impact on the gastric and caecal microbiota of rabbits ..................................................................................................................................... 132 Statement of authorship ...................................................................................................... 133 Original article ...................................................................................................................... 136 Supplementary information ................................................................................................ 147 i Chapter 8 General Discussion ................................................................................................. 151 8.1. General summary ......................................................................................................... 152 8.2. Major findings .............................................................................................................. 153 8.2.1. Comparative rates of AMR in Australia is low for Gram-negative pathogens but moderately high for Gram-positive pathogens ................................................................ 153 8.2.2. High levels of AMR among bacterial isolates from veterinary healthcare-associated infections .......................................................................................................................... 154 8.2.3. Resistance to antimicrobials that are critical to human care remains either undetected or low among companion animal isolates from Australia ............................ 156 8.2.4. Oral pradofloxacin has different effects on gastric, caecal and faecal microbial diversity ............................................................................................................................ 157 8.2.5. Pradofloxacin is safe for use in rabbits ................................................................... 158 8.3. Implication of findings and future works ....................................................................... 159 8.4. Conclusions .................................................................................................................... 160 8.5. References ..................................................................................................................... 162 ii Acknowledgements In the name of Allah, the Most Gracious and the Most Merciful. Alhamdulillah, I praise and thank Allah SWT for giving me the strength and courage to complete my study. I would like to offer my sincerest gratitude to my principal supervisor, Professor Darren J. Trott, who has supported me throughout my study with his knowledge, patience, encouragement and superb supervision. Without him, I won’t be able to finish my journey as a PhD student. Sincere thanks to Professor Gordon Howarth for his valuable advice, consultation and encouragement; Professor David Jordan for his wonderful support, kindness, helping me with statistical analysis and writing; Dr Sam Abraham for the guide during my first year of study and for the opportunity to finish AMR survey project, Assoc. Professor Jacqueline Norris and Dr Kate Worthing for brilliant research collaboration and valuable comments on the paper, Prof. John Turnidge and Ms Jan Bell for valuable advice on antimicrobial resistance. Special thanks to koala, rabbit and microbiome-research group, Dr Natasha Speight, Dr Esmaeil Ebrahimie and Dr Manijeh Mohammadi-Dehcheshmeh which I have been involved in and got more knowledge in the field. I would like to express my appreciation to Ms Niranjala Seimon from International Sponsored Student Advisor/Australia Awards Liaison Officer, for continuous support over the years. Special thanks to Lesley Menzel, Rebecca Dunbar, and David Purdie for the support during my first years stay at Roseworthy Residential College. To all of my friends, Saad Gilani (with Anne Marie and Haiqa) and Noor Haliza Hasan, thank you for the inspiration, you were brilliant students. Pardeep Sharma, Abd and Bedur, Wei Yee Chan, Nadia Zulkifli, Entesar Shuhaib, Farida Mazumder, Sri Dwi Hastuti, Janet Pandi, Sangay Tenzin, Alex, Vivek Pande, Vaibhav Gole, Consuela Estrella, thank you for the friendship and wonderful moment during my study. Special thanks to my colleague, Neil Griffiths, Shangzhe Xie, Jessica Fabijan, Amanda Kidsley, Elizabeth Hickey, Vanessa Tamlin, Mandy Bowling, Mohinder Singh, Oliver Wilkins, Shewli Mukerjee, Arthur Mason, Richelle Butcher, Nicola Woodward, Caitlyn Page and other DVM students. Finally, I would like to extend my thanks to my family, I can never say enough thanks to my parents, Ibu Siti Sugiarti and Bapak Daryono who always pray for me and support me anytime, anywhere, throughout
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0163484 A1 Heep Et Al
    US 200901 63484A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0163484 A1 Heep et al. (43) Pub. Date: Jun. 25, 2009 (54) PHARMACEUTICALS CONTAINING (30) Foreign Application Priority Data FLUOROQUINOLONES (75) Inventors: Iris Heep, Köln (DE); Kristine Mar. 8, 2006 (DE) ......................... 102O06O10642.3 Rigi,R. Dormagen Publication Classification (DE); Markus Edingloh, (51) Int. Cl. Leverkusen (DE) A 6LX 3/5.395 (2006.01) Correspondence Address: A63/496 (2006.01) BSER HEALTHCARE LLC A 6LX 3L/24709 (2006.01) P.O.BOX390 A6II 47/20 (2006.01) SHAWNEE MISSION, KS 66201 (US) A6IP3L/04 (2006.01) (73) Assignee: BAYER ANIMAL, HEALTH (52) U.S. Cl. ................. 514/229.2: 514/253.08: 514/300; GMBH, LEVERKUSEN (DE) 514/769; 514/772 (21) Appl. No.: 12/280,996 (57) ABSTRACT (22) PCT Filed: Feb. 23, 2007 The invention relates to pharmaceutical formulations in liq uid form, containing fluoroquinolones and antioxidative Sul (86). PCT No.: PCT/EP2007/001568 phur compounds. The formulations are particularly Suitable S371 (c)(1), for parenteral uses and are distinguished, interalia, by good (2), (4) Date: Oct. 31, 2008 tolerance. US 2009/0163484 A1 Jun. 25, 2009 PHARMACEUTICALS CONTAINING reconstitution, or must be discarded directly as the result of FLUOROQUINOLONES the possibility of particle formation. Accordingly, a ready-to use solution is advantageous as solution for injection. 0006. It is furthermore necessary that a suitable amount of the fluoroquinolone enters the serum after the administration, 0001. The invention relates to pharmaceutical formula as this is also described in WO99/29322. Again, this is not a tions in liquid form comprising fluoroquinolones and antioxi matter of course with injectable fluoroquinolone formula dant Sulphur compounds.
    [Show full text]
  • The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity
    molecules Review The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity Abdul Naeem 1, Syed Lal Badshah 1,2,*, Mairman Muska 1, Nasir Ahmad 2 and Khalid Khan 2 1 National Center of Excellence in Physical Chemistry, University of Peshawar, Peshawar, Khyber Pukhtoonkhwa 25120, Pakistan; [email protected] (A.N.); [email protected] (M.M.) 2 Department of Chemistry, Islamia College University Peshawar, Peshawar, Khyber Pukhtoonkhwa 25120, Pakistan; [email protected] (N.A.); [email protected] (K.K.) * Correspondence: [email protected]; Tel.: +92-331-931-6672 Academic Editor: Peter J. Rutledge Received: 23 December 2015 ; Accepted: 15 February 2016 ; Published: 28 March 2016 Abstract: Quinolones are broad-spectrum synthetic antibacterial drugs first obtained during the synthesis of chloroquine. Nalidixic acid, the prototype of quinolones, first became available for clinical consumption in 1962 and was used mainly for urinary tract infections caused by Escherichia coli and other pathogenic Gram-negative bacteria. Recently, significant work has been carried out to synthesize novel quinolone analogues with enhanced activity and potential usage for the treatment of different bacterial diseases. These novel analogues are made by substitution at different sites—the variation at the C-6 and C-8 positions gives more effective drugs. Substitution of a fluorine atom at the C-6 position produces fluroquinolones, which account for a large proportion of the quinolones in clinical use. Among others, substitution of piperazine or methylpiperazine, pyrrolidinyl and piperidinyl rings also yields effective analogues. A total of twenty six analogues are reported in this review. The targets of quinolones are two bacterial enzymes of the class II topoisomerase family, namely gyrase and topoisomerase IV.
    [Show full text]
  • Belgian Veterinary Surveillance of Antibacterial Consumption National
    Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2020 Publication : 22 June 2021 1 SUMMARY This annual BelVet-SAC report is now published for the 12th time and describes the antimicrobial use (AMU) in animals in Belgium in 2020 and the evolution since 2011. For the third year this report combines sales data (collected at the level of the wholesalers-distributors and the compound feed producers) and usage data (collected at farm level). This allows to dig deeper into AMU at species and farm level in Belgium. With a consumption of 87,6 mg antibacterial compounds/kg biomass an increase of +0.2% is seen in 2020 in comparison to 2019. The increase seen in 2020 is spread over both pharmaceuticals (+0.2%) and antibacterial premixes (+4.0%). This unfortunately marks the end of a successful reduction in antibacterial product sales that was seen over the last 6 years resulting in a cumulative reduction of -40,2% since 2011. The gap seen in the coverage of the sales data with the Sanitel-Med collected usage data increased substantially compared to 2019, meaning continuous efforts need to be taken to ensure completeness of the collected usage data. When looking at the evolution in the number of treatment days (BD100) at the species level, as calculated from the SANITEL- MED use data, use increased in poultry (+5,0%) and veal calves (+1,9%), while it decreased in pigs (-3,1%). However, the numerator data for this indicator remain to be updated for 2020, potentially influencing the reliability of the result.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Revisión Bibliográfica
    Vol. 34 (1), Marzo 2017. ISSN 1409-0015 Medicina Legal de Costa Rica - Edición Virtual REVISIÓN BIBLIOGRÁFICA Antibioticoterapia y nuevas terapias no farmacológicas en infecciones por Clostridium difficile Barrientos Jiménez, Maryam1; Esquivel Zúñiga, María Rebeca2; 3 4 5 Álvarez Umaña Silvia Vanessa ; Tencio Araya, Jose ; Soto Cerdas Jahaira Resumen: La infección por Clostridium difficile es la principal causa de diarrea infecciosa en pacientes hospitalizados. Los pacientes pueden ser portadores asintomáticos o presentar desde una diarrea leve a una colitis pseudomembranosa, megacolon tóxico, sepsis y muerte. El manejo de esta infección sigue presentando puntos de controversia, tanto en la elección del mejor método diagnóstico como en el tratamiento. En los casos en los cuales la infección por este agente fue confirmada la primera y más efectiva medida es suspender la antibioticoterapia que el paciente este recibiendo, en la medida de lo posible. El tratamiento se basa en tres agentes clásicos: metronidazol, vancomicina y teicoplanina con la más reciente adición de fidaxomicina y ridinilazol. Pacientes con presentación severa muchas veces requieren resolución quirúrgica además de las medidas de soporte y monitoreo. El objetivo de esta revisión es ofrecer información actualizada sobre la patogénesis y estrategias terapéuticas sobre el manejo de la infección por este patógeno. Palabras claves: Clostridium difficile, infección por Clostridium difficile, colitis pseudomembranosa. Fuente: MeSH Abstract: Clostridium difficile infection is the leading cause of hospital acquired diarrhea. The patients can be asymptomatic carriers or present a mild diarrhea, a pseudomembranous colitis, toxic megacolon, sepsis and death. There is controversy in this infection’s including the best method of diagnosis and also regarding therapeutic regimen.
    [Show full text]
  • Ridinilazole: a Novel Antimicrobial for Clostridium Difficile Infection
    REVIEW ARTICLE Annals of Gastroenterology (2019) 32, 134-140 Ridinilazole: a novel antimicrobial for Clostridium difficile infection Jonathan C. Choa, Matthew P. Crottyb, Joe Pardoc The University of Texas at Tyler, Tyler, TX; Methodist Dallas Medical Center, Dallas, TX; North FL/South GA Veterans Health System, Gainesville, FL, USA Abstract Clostridium difficile (C. difficile) infection remains a global healthcare threat worldwide and the limited options available for its treatment are of particular concern. Ridinilazole is one potential future agent, as it demonstrates rapid bactericidal activity against C. difficile. Current studies show that ridinilazole has a lower propensity for collateral damage to the gut microbiome and appears to diminish the production of C. difficile toxins. Results from phase II studies demonstrate that patients receiving ridinilazole had a higher sustained clinical response compared with patients receiving vancomycin (66.7% vs. 42.4%; P=0.0004). Adverse reactions were similar between ridinilazole and vancomycin (40% vs. 56%, respectively), with most being gastrointestinal-related. Nausea (20%) and abdominal pain (12%) were the most commonly reported adverse reactions associated with ridinilazole. Phase II study results are promising and future availability of phase III trial results will help further delineate the role and value of ridinilazole. Keywords Ridinilazole, Clostridium difficile, infectious diarrhea Ann Gastroenterol 2019; 32 (2): 134-140 Introduction aspects of managing patients with C. difficile is the pathogen’s propensity to cause recurrent infections. Recurrence rates Clostridium difficile (C. difficile) is recognized as an urgent of up to 25% have been reported following treatment with metronidazole or vancomycin [14,15]. The vicious cycle of threat to human health and represents an extremely challenging recurrence continues further, with patients who have one pathogen, given its impact on the healthcare system [1-5].
    [Show full text]
  • The Genera Staphylococcus and Macrococcus
    Prokaryotes (2006) 4:5–75 DOI: 10.1007/0-387-30744-3_1 CHAPTER 1.2.1 ehT areneG succocolyhpatS dna succocorcMa The Genera Staphylococcus and Macrococcus FRIEDRICH GÖTZ, TAMMY BANNERMAN AND KARL-HEINZ SCHLEIFER Introduction zolidone (Baker, 1984). Comparative immu- nochemical studies of catalases (Schleifer, 1986), The name Staphylococcus (staphyle, bunch of DNA-DNA hybridization studies, DNA-rRNA grapes) was introduced by Ogston (1883) for the hybridization studies (Schleifer et al., 1979; Kilp- group micrococci causing inflammation and per et al., 1980), and comparative oligonucle- suppuration. He was the first to differentiate otide cataloguing of 16S rRNA (Ludwig et al., two kinds of pyogenic cocci: one arranged in 1981) clearly demonstrated the epigenetic and groups or masses was called “Staphylococcus” genetic difference of staphylococci and micro- and another arranged in chains was named cocci. Members of the genus Staphylococcus “Billroth’s Streptococcus.” A formal description form a coherent and well-defined group of of the genus Staphylococcus was provided by related species that is widely divergent from Rosenbach (1884). He divided the genus into the those of the genus Micrococcus. Until the early two species Staphylococcus aureus and S. albus. 1970s, the genus Staphylococcus consisted of Zopf (1885) placed the mass-forming staphylo- three species: the coagulase-positive species S. cocci and tetrad-forming micrococci in the genus aureus and the coagulase-negative species S. epi- Micrococcus. In 1886, the genus Staphylococcus dermidis and S. saprophyticus, but a deeper look was separated from Micrococcus by Flügge into the chemotaxonomic and genotypic proper- (1886). He differentiated the two genera mainly ties of staphylococci led to the description of on the basis of their action on gelatin and on many new staphylococcal species.
    [Show full text]
  • The Grohe Method and Quinolone Antibiotics
    The Grohe method and quinolone antibiotics Antibiotics are medicines that are used to treat bacterial for modern fluoroquinolones. The Grohe process and the infections. They contain active ingredients belonging to var- synthesis of ciprofloxacin sparked Bayer AG’s extensive ious substance classes, with modern fluoroquinolones one research on fluoroquinolones and the global competition of the most important and an indispensable part of both that produced additional potent antibiotics. human and veterinary medicine. It is largely thanks to Klaus Grohe – the “father of Bayer quinolones” – that this entirely In chemical terms, the antibiotics referred to for simplicity synthetic class of antibiotics now plays such a vital role for as quinolones are derived from 1,4-dihydro-4-oxo-3-quin- medical practitioners. From 1965 to 1997, Grohe worked oline carboxylic acid (1) substituted in position 1. as a chemist, carrying out basic research at Bayer AG’s Fluoroquinolones possess a fluorine atom in position 6. In main research laboratory (WHL) in Leverkusen. During this addition, ciprofloxacin (2) has a cyclopropyl group in posi- period, in 1975, he developed the Grohe process – a new tion 1 and also a piperazine group in position 7 (Figure A). multi-stage synthesis method for quinolones. It was this This substituent pattern plays a key role in its excellent achievement that first enabled him to synthesize active an- antibacterial efficacy. tibacterial substances such as ciprofloxacin – the prototype O 5 O 4 3 6 COOH F COOH 7 2 N N N 8 1 H N R (1) (2) Figure A: Basic structure of quinolone (1) (R = various substituents) and ciprofloxacin (2) Quinolones owe their antibacterial efficacy to their inhibition This unique mode of action also makes fluoroquinolones of essential bacterial enzymes – DNA gyrase (topoisomer- highly effective against a large number of pathogenic ase II) and topoisomerase IV.
    [Show full text]
  • Ridinilazole—A Novel Antibiotic for Treatment of Clostridium Difficile Infection
    120 Editorial Ridinilazole—a novel antibiotic for treatment of Clostridium difficile infection Niels Steinebrunner, Wolfgang Stremmel, Karl H. Weiss Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany Correspondence to: Prof. Karl Heinz Weiss, MD. Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg 69120, Germany. Email: [email protected]. Provenance: This is an invited Editorial commissioned by Section Editor Dr. Ming Zhong (Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China). Comment on: Vickers RJ, Tillotson GS, Nathan R, et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis 2017;17:735-44. Submitted Dec 04, 2017. Accepted for publication Dec 18, 2017. doi: 10.21037/jtd.2017.12.117 View this article at: http://dx.doi.org/10.21037/jtd.2017.12.117 Clostridium difficile (C. difficile) infection has become a major completing initial therapy. Risk factors for recurrence of health problem worldwide and is considered to be one of CDI include gastric acid suppression by proton pump the most common hospital-acquired (nosocomial) infections inhibitor therapy, gastrointestinal tract surgery, underlying with increasing incidence and severity (1). In Germany, immunosuppression (malignancy, cirrhosis, chemotherapy, the number of C. difficile infections (CDI) increased from immunosuppressive therapy), as well as older age 7 to 39 reported cases per 100,000 hospitalized patients (>65 years) of affected patients (6-11). Recurrent infections between 2000 and 2004, with yet another doubling of are associated with an increased risk of further episodes of numbers between 2004 and 2006 (2).
    [Show full text]
  • IX Updating Course of Antimicrobials and Infectious Diseases
    REVISTA ESPAÑOLA DE QQuimioterapiauimioterapia SPANISH JOURNAL OF CHEMOTHERAPY ISSN: 0214-3429 Volume 32 Supplement number 2 September 2019 Pages: 01-79 IX Updating Course of Antimicrobials and Infectious Diseases Coordination: Dr. FJ. Candel González Servicio de Microbiologia Clínica Hospital Clínico San Carlos Madrid. Spain. 18 y 19 de febrero de 2019 Auditorio San Carlos. Pabellón Docente Publicación Oficial Hospital Clínico San Carlos de la Sociedad Española de Quimioterapia REVISTA ESPAÑOLA DE Quimioterapia Revista Española de Quimioterapia tiene un carácter multidisciplinar y está dirigida a todos aquellos profesionales involucrados en la epidemiología, diagnóstico, clínica y tratamiento de las enfermedades infecciosas Fundada en 1988 por la Sociedad Española de Quimioterapia Sociedad Española de Quimioterapia Indexada en Publicidad y Suscripciones Publicación que cumple los requisitos de Science Citation Index Sociedad Española de Quimioterapia soporte válido Expanded (SCI), Dpto. de Microbiología Index Medicus (MEDLINE), Facultad de Medicina ISSN Excerpta Medica/EMBASE, Avda. Complutense, s/n 0214-3429 Índice Médico Español (IME), 28040 Madrid Índice Bibliográfico en Ciencias e-ISSN de la Salud (IBECS) 1988-9518 Atención al cliente Depósito Legal Secretaría técnica Teléfono 91 394 15 12 M-32320-2012 Dpto. de Microbiología Correo electrónico Facultad de Medicina [email protected] Maquetación Avda. Complutense, s/n Kumisai 28040 Madrid [email protected] Consulte nuestra página web Impresión Disponible en Internet: www.seq.es España www.seq.es Esta publicación se imprime en papel no ácido. This publication is printed in acid free paper. LOPD Informamos a los lectores que, según lo previsto © Copyright 2019 en el Reglamento General de Protección Sociedad Española de de Datos (RGPD) 2016/679 del Parlamento Quimioterapia Europeo, sus datos personales forman parte de la base de datos de la Sociedad Española de Reservados todos los derechos.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]